rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2015-367-370rsp-2105Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHHLA-B5/51-генотип: связь с клиническими проявлениями болезни БехчетаHLA-B5/51 GENOTYPE: AN ASSOCIATION WITH THE CLINICAL MANIFESTATIONS OF BEHCET’S DISEASEАлекбероваЗ. С.AlekberovaZ. S.zalekberova@inbox.ruИзмаиловаФ. И.IzmailovaF. I.ГусеваИ. А.GusevaI. A.ДенисовЛ. Н.DenisovL. N.ГлуховаС. И.GlukhovaS. I.ПопковаТ. В.PopkovaT. V.ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34АРоссияV.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522Russian FederationV.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522Russian Federation201510092015534367370Copyright © Алекберова З.С., Измаилова Ф.И., Гусева И.А., Денисов Л.Н., Глухова С.И., Попкова Т.В., 20152015Алекберова З.С., Измаилова Ф.И., Гусева И.А., Денисов Л.Н., Глухова С.И., Попкова Т.В.Alekberova Z.S., Izmailova F.I., Guseva I.A., Denisov L.N., Glukhova S.I., Popkova T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2105

Цель – оценить вклад HLA-B5/51 в экспрессию клинических проявлений и степень риска возникновения болезни Бехчета (ББ) в двух этнических группах.

Материал и методы

Материал и методы. 146 больных с ББ, соответствующих Международным критериям ICBD, были разделены по этническому признаку на две группы. В группу I включены 86 пациентов из Дагестана (представители 8 этнических народностей этого региона), средний возраст составил 30,7±9,6 года, длительность болезни – 8,8±10,1 года. В группу II вошли 60 русских пациентов, не проживающих на территории Дагестана, средний возраст 32,9±11,1 года, длительность заболевания – 11,2±10,1 года. Все больные обследованы в ФГБНУ НИИРим. В.А. Насоновой в период с 1990 по 2014 г. Типирование антигенов HLA класса I осуществляли микролимфоцитотоксическим методом с использованием набора антилейкоцитарных сывороток «Гисанс» (Санкт-Петербург).

Результаты

Результаты. HLA-B5/51 был обнаружен у 87 (59,6%) больных. У мужчин он встречался значительно чаще, чем у женщин (70 и 38% соответственно; p<0,01). Язвы гениталий и узловатая эритема у позитивных по HLA-B5/51 дагестанцев выявлялась значительно чаще (87,3 и 57%), чем у негативных (56,5 и 26%; p=0,0019 и р=0,01 соответственно). Достоверных различий по этим параметрам в русской когорте пациентов с ББ в зависимости от наличия этой аллели не установлено. Риск развития узловатой эритемы у мужчин-дагестанцев с ББ, позитивных по HLA-B5/51, в 2 раза выше, чем у HLA-B5/51-негативных пациентов (p=0,054). Риск возникновения язв гениталий и генерализованного увеита у женщин-дагестанок с HLA-B5/51-носительством оказался выше соответственно в 3,5 (p=0,057) и в 2,7 раза по сравнению с отрицательными по этому гену пациентами. Частота HLA-B5/51 среди дагестанцев составила 73,2%, среди русских – 40%. Кроме того, в нашем исследовании носительство HLA-B5/51 выявлялось преимущественно у пациентов мужского пола. Следовательно, наряду с этнической принадлежностью, при анализе клинических ассоциаций с HLA-B5/51 должен учитываться пол больных

Objective

Objective: to estimate the contribution of HLA-B5/51 genotype to the clinical manifestations and risk of Behcet’s disease (BD) in two ethnic groups.

Subjects and methods

Subjects and methods. 146 BD patients fulfilling the International Criteria for BD (ICBD) were divided into two ethnic groups: 1) 86 patients from Dagestan (representatives of 8 ethnic nationalities in this region) with mean age 30.7±9.6 years; disease duration – 8.8±10.1 years; 2) 60 ethnic Russian patients, nonresidents of Dagestan with mean age 32.9±11.1 years; disease duration – 11.2±10.1 years. All patients were examined at the V.A. Nasonova Research Institute of Rheumatology in 1990 to 2014. HLA class I antigens were typed by a microlymphocytotoxic technique using a Gisans anti-leukocyte sera kit (Saint Petersburg).

Results

Results. HLA-B5/51 was detected in 87 (59.6%) patients, much more often in men than in women (70 and 38%, respectively; p<0.01). Genital ulcers and erythema nodosum were significantly more common in HLA-B5/51-positive Dagestani (87.3 and 57%) than in HLA-B5/51-negative ones (56.5 and 26%; p=0.0019 and р=0.01; respectively). There were no significant differences in these signs in the Russian group of patients with BD depending on the presence of this allele. In HLA-B5/51-positive male Dagestani patients with BD, the risk of erythema nodosum was twice as high as that in HLA-B5/51-negative patients (p=0.054). In HLA-B5/51 female Dagestani carriers, the risk of genital ulcers and generalized uveitis proved to be 3.5 (p=0.057) and 2.7 times higher than that in HLA-B5/51 noncarriers. Frequency of HLA-B5/51 was 73.2% among the Dagestanis and 40% among the Russians. Furthermore, this investigation revealed HLA-B5/51 carriage mainly in the male BD patients. Therefore, in addition to ethnicity, gender should be borne in mind when analyzing the clinical associations with HLA-B5/51.

болезнь БехчетаэтносполHLA-типированиеBehсet’s diseaseethnosgenderHLA typingReferencesMat C, Yurdakul S, Sevim A, et al. Syndrome: facts and controversies. Clin Dermatol. 2013;31:352–61. doi: 10.1016/j.clindermatol. 2013.01.002Mat C, Yurdakul S, Sevim A, et al. Syndrome: facts and controversies. Clin Dermatol. 2013;31:352–61. doi: 10.1016/j.clindermatol. 2013.01.002Ohno S, Ohguchi M, Hirose S, et al. Close association of HLA Bw 51 with Behcet’s disease. Arch Ophthalmol. 1982;100:1455–8. doi: 10.1001/archopht.1982.01030040433013Ohno S, Ohguchi M, Hirose S, et al. Close association of HLA Bw 51 with Behcet’s disease. Arch Ophthalmol. 1982;100:1455–8. doi: 10.1001/archopht.1982.01030040433013Mahr A, Belarbi L, Wechsler B, et al. Population-based prevalence study of Behcet’s disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum. 2008;58(12):3951–9. doi: 10.1002/art.24149Mahr A, Belarbi L, Wechsler B, et al. Population-based prevalence study of Behcet’s disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum. 2008;58(12):3951–9. doi: 10.1002/art.24149Maldini C, Lavalley MP, Cheminant M, et al. Relationships of HLA-B51or B5 genotype with Behcet’s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology. 2012;51(5):887–900. doi: 10.1093/rheumatology/ker428Maldini C, Lavalley MP, Cheminant M, et al. Relationships of HLA-B51or B5 genotype with Behcet’s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology. 2012;51(5):887–900. doi: 10.1093/rheumatology/ker428Chang Y, Tsai S, Lia O. A genetic srudy of Behcet’s disease in Taiwan Chinese. Tissue Antigens. 1987;30:68–72. doi: 10.1111/j.1399-0039.1987.tb01599.xChang Y, Tsai S, Lia O. A genetic srudy of Behcet’s disease in Taiwan Chinese. Tissue Antigens. 1987;30:68–72. doi: 10.1111/j.1399-0039.1987.tb01599.xMuftuoglu A, Yazici H, Yurdakul S, et al. Behcet’s disease: back of correlation of of clinical manifestations with HLA antigens. Tissue Antigens. 1981;17:226–30. doi: 10.1111/j.1399-0039.1981.tb00687.xMuftuoglu A, Yazici H, Yurdakul S, et al. Behcet’s disease: back of correlation of of clinical manifestations with HLA antigens. Tissue Antigens. 1981;17:226–30. doi: 10.1111/j.1399-0039.1981.tb00687.xZouboulis Ch, Kotter I, Djawari D, et al. Epidemiological features of Adamantiades–Behcet’s disease in Germany and in Europe. Yonsei Med J. 1997;38(6):411–22. doi: 10.3349/ymj.1997.38.6.411Zouboulis Ch, Kotter I, Djawari D, et al. Epidemiological features of Adamantiades–Behcet’s disease in Germany and in Europe. Yonsei Med J. 1997;38(6):411–22. doi: 10.3349/ymj.1997.38.6.411O’Duffy J, Taswell H, Elverback L. HLA antigens in Behcet’s disease. J Rheumatol. 1978;3:1–3.O’Duffy J, Taswell H, Elverback L. HLA antigens in Behcet’s disease. J Rheumatol. 1978;3:1–3.Голоева РГ, Алекберова ЗС, Гусева ИА, Крылов МЮ. Болезнь Бехчета и ассоциация с антигеном HLA B5. Терапевтический архив. 2010;(5):45–50 [Goloeva RG, Alekberova ZS, Guseva IA, Krylov MYu. Behcet's disease and the association with the antigen HLA B5. Terapevticheskii arkhiv. 2010;(5):45–50 (In Russ.)].Голоева РГ, Алекберова ЗС, Гусева ИА, Крылов МЮ. Болезнь Бехчета и ассоциация с антигеном HLA B5. Терапевтический архив. 2010;(5):45–50 [Goloeva RG, Alekberova ZS, Guseva IA, Krylov MYu. Behcet's disease and the association with the antigen HLA B5. Terapevticheskii arkhiv. 2010;(5):45–50 (In Russ.)].Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet's Disease. Lancet. 1990;335(8697):1078–80.Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet's Disease. Lancet. 1990;335(8697):1078–80.Choukri F, Chakib A, Himmich H, et al. HLA B51 and B15 alleles confer predisposition to Behcet’s disease in Moroccan patients. Hum Immunol. 2001;62:180–5. doi: 10.1016/S0198-Choukri F, Chakib A, Himmich H, et al. HLA B51 and B15 alleles confer predisposition to Behcet’s disease in Moroccan patients. Hum Immunol. 2001;62:180–5. doi: 10.1016/S0198-(00)00249-4(00)00249-4Kilmartin D, Finch A, Asherson R. Primary association of HLA B51 with Behcet’s disease in Ireland. Br J Ophthalmol. 1997;61:649–53. doi: 10.1136/bjo.81.8.649Kilmartin D, Finch A, Asherson R. Primary association of HLA B51 with Behcet’s disease in Ireland. Br J Ophthalmol. 1997;61:649–53. doi: 10.1136/bjo.81.8.649Kang E, Kim JY, Takeuchi F, et al. Associations between the HLA-A polymorphism and the clinical manifestations of Behcet’s disease. Arthritis Res Ther. 2011;13:R49. doi: 10.1186/ar3292Kang E, Kim JY, Takeuchi F, et al. Associations between the HLA-A polymorphism and the clinical manifestations of Behcet’s disease. Arthritis Res Ther. 2011;13:R49. doi: 10.1186/ar3292Kobashigawa et al. Yokohama 15th Intern. Conference of Behcet’s disease. 2012; Abstract book. 2012. P. 117.Kobashigawa et al. Yokohama 15th Intern. Conference of Behcet’s disease. 2012; Abstract book. 2012. P. 117.Kobayashi T, Kishimoto M, Swearingen C, et al. Differences in clinical manifestations treatment and, concordance rates with two major sets of criteria for Behcet’s syndrome for patients in the USA and Japan: data from a large three-center cohort study. Mod Rheumatol. 2013;23(3):547–53. doi: 10.3109/s10165-012-0696-8Kobayashi T, Kishimoto M, Swearingen C, et al. Differences in clinical manifestations treatment and, concordance rates with two major sets of criteria for Behcet’s syndrome for patients in the USA and Japan: data from a large three-center cohort study. Mod Rheumatol. 2013;23(3):547–53. doi: 10.3109/s10165-012-0696-8Bonitsis N, Micheli C, Mahr A, et al. Comparison of demographic and clinical characteristics according to HLA B5 states based on the German registry of Adamatiades–Behcet’s disease. 15th International Conference on Behcet’s Disease. Abstract book. 13–15th july 2012; p 5-2-097. P. 118.Bonitsis N, Micheli C, Mahr A, et al. Comparison of demographic and clinical characteristics according to HLA B5 states based on the German registry of Adamatiades–Behcet’s disease. 15th International Conference on Behcet’s Disease. Abstract book. 13–15th july 2012; p 5-2-097. P. 118.Ombrello M, Kirino Y, de Bakker P, et al. Behcet disease-associated MHC class I redues implicate antigen binding and regulation of cell-mediated cytotoxity. Proc Natl Acad Sci USA. 2014 Jun 17;111(24):8867–72. doi: 10.1073/pnas.1406575111. Epub 2014 May 12.Ombrello M, Kirino Y, de Bakker P, et al. Behcet disease-associated MHC class I redues implicate antigen binding and regulation of cell-mediated cytotoxity. Proc Natl Acad Sci USA. 2014 Jun 17;111(24):8867–72. doi: 10.1073/pnas.1406575111. Epub 2014 May 12.Wallace G. HLA-B51 the primary risk in Behcet disease. Proc Natl Acad Sci USA. 2014 Jun 17;111(24):8706–7. doi: 10.1073/pnas.1407307111. Epub 2014 May 29Wallace G. HLA-B51 the primary risk in Behcet disease. Proc Natl Acad Sci USA. 2014 Jun 17;111(24):8706–7. doi: 10.1073/pnas.1407307111. Epub 2014 May 29

The authors declare that there are no conflicts of interest present.